Cornell Uiversity, Ithaca, NY 1972- Biology
Albany Medical School, Albany, NY M.D. 1976 Medicine
Fitzsimons Army Medical Center, Denver, CO 1979 Internal Medicine
Walter Reed Army Medical Center, Washington, DC 1982 Infectious Disease fellowship
| Cunha CB, Opal SM. "Antibiotic Stewardship: Strategies to Minimize Antibiotic Resistance While Maximizing Antibiotic Effectiveness." The Medical clinics of North America, vol. 102, no. 5, 2018, pp. 831-843. |
| Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, Vincent JL, Werdan K, Martin-Loeches I, Almirall J, Artigas A, Ignacio Ayestarán J, Nuding S, Ferrer R, Sirgo Rodríguez G, Shankar-Hari M, Álvarez-Lerma F, Riessen R, Sirvent JM, Kluge S, Zacharowski K, Bonastre Mora J, Lapp H, Wöbker G, Achtzehn U, Brealey D, Kempa A, Sánchez García M, Brederlau J, Kochanek M, Reschreiter HP, Wise MP, Belohradsky BH, Bobenhausen I, Dälken B, Dubovy P, Langohr P, Mayer M, Schüttrumpf J, Wartenberg-Demand A, Wippermann U, Wolf D, Torres A. "Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)." Intensive care medicine, vol. 44, no. 4, 2018, pp. 438-448. |
| Lewis RJ, Angus DC, Laterre PF, Kjølbye AL, van der Meulen E, Blemings A, Graves T, Russell JA, Carlsen JE, Jacobsen K, Yealy DM, Opal SM, Windeløv NA, François B, Perner A, Pickkers P, Berry SM. "Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial." Annals of the American Thoracic Society, vol. 15, no. 2, 2018, pp. 250-257. |
| Banerjee D, Monaghan S, Zhao R, Walsh T, Palmisciano A, Phillips GS, Opal S, Levy MM. "Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis." Critical Care, vol. 22, no. 1, 2018, pp. 146. |
| Rello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, Netea MG, Nseir S, Opal SM, van de Veerdonk FL, Wilcox MH, Wiersinga WJ. "Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 24, no. 12, 2018, pp. 1264-1272. |
| Chahin AB, Opal JM, Opal SM. "Whatever happened to the Shwartzman phenomenon?." Innate Immunity, vol. 24, no. 8, 2018, pp. 466-479. |
| Banerjee, Debasree, Opal, Steven M. "Age, exercise, and the outcome of sepsis." Critical Care, vol. 21, no. 1, 2017. |
| Banerjee D, Opal SM. "Age, exercise, and the outcome of sepsis." Critical Care, vol. 21, no. 1, 2017, pp. 286. |
| Caffrey, Aisling R., Timbrook, Tristan T., Noh, Eunsun, Sakoulas, George, Opal, Steven M., Nizet, Victor, LaPlante, Kerry L. "Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia." Antimicrobial Agents and Chemotherapy, vol. 61, no. 3, 2017, pp. e02228-16. |
| Zorzopulos J, Opal SM, Hernando-Insúa A, Rodriguez JM, Elías F, Fló J, López RA, Chasseing NA, Lux-Lantos VA, Coronel MF, Franco R, Montaner AD, Horn DL. "Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy." World journal of stem cells, vol. 9, no. 3, 2017, pp. 45-67. |
| Chahin, Abdullah, Opal, Steven M. "Severe Pneumonia Caused by Legionella pneumophila: Differential Diagnosis and Therapeutic Considerations." Infectious Disease Clinics of North America, vol. 31, no. 1, 2017, pp. 111-121. |
| Opal SM. "Source Control in Sepsis Urgent or Not So Fast?." Critical care medicine, vol. 45, no. 1, 2017, pp. 130-132. |
| Opal, Steven M. "Source Control in Sepsis Urgent or Not So Fast?*." Critical Care Medicine, vol. 45, no. 1, 2017, pp. 130-132. |
| Shea BS, Opal SM. "The Role of S1PR3 in Protection from Bacterial Sepsis." American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 12, 2017, pp. 1500-1502. |
| North, John R., Takenaka, Shunsuke, Rozek, Annett, Kielczewska, Agnieszka, Opal, Steven, Morici, Lisa A., Finlay, B.Brett, Schaber, Christopher J., Straube, Richard, Donini, Oreola. "A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy." Journal of Biotechnology, vol. 226, 2016, pp. 24-34. |
| North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O. "A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy." Journal of Biotechnology, vol. 226, 2016, pp. 24-34. |
| Angus DC, Opal S. "Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story." JAMA, vol. 315, no. 14, 2016, pp. 1457-9. |
| Opal, S. "Infectious complications of biologic therapeutics." International Journal of Infectious Diseases, vol. 45, 2016, pp. 50-51. |
| Yende S, Austin S, Rhodes A, Finfer S, Opal S, Thompson T, Bozza FA, LaRosa SP, Ranieri VM, Angus DC. "Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials." Critical care medicine, vol. 44, no. 8, 2016, pp. 1461-7. |
| Opal, S. "New therapeutics for sepsis." International Journal of Infectious Diseases, vol. 45, 2016, pp. 64. |
| Fedson DS, Jacobson JR, Rordam OM, Opal SM. "Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?"." mBio, vol. 7, no. 1, 2016, pp. e00094-16. |
| Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. "Sepsis and septic shock." Nature reviews. Disease primers, vol. 2, 2016, pp. 16045. |
| Chawla, Lakhmir S., Fink, Mitchell, Goldstein, Stuart L., Opal, Steven, Gómez, Alonso, Murray, Patrick, Gómez, Hernando, Kellum, John A. "THE EPITHELIUM AS A TARGET IN SEPSIS." Shock, vol. 45, no. 3, 2016, pp. 249-258. |
| Chawla LS, Fink M, Goldstein SL, Opal S, Gómez A, Murray P, Gómez H, Kellum JA, ADQI XIV Workgroup. "THE EPITHELIUM AS A TARGET IN SEPSIS." Shock, vol. 45, no. 3, 2016, pp. 249-58. |
| Giamarellos-Bourboulis, Evangelos J., Opal, Steven M. "The role of genetics and antibodies in sepsis." Annals of Translational Medicine, vol. 4, no. 17, 2016, pp. 328-328. |
| Giamarellos-Bourboulis EJ, Opal SM. "The role of genetics and antibodies in sepsis." Annals of Translational Medicine, vol. 4, no. 17, 2016, pp. 328. |
| Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. "The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)." JAMA, vol. 315, no. 8, 2016, pp. 801-10. |
| Welte, Tobias, Dellinger, R. Phillip, Ebelt, Henning, Ferrer, Miquel, Opal, Steven M., Schliephake, Dorothee E., Wartenberg-Demand, Andrea, Werdan, Karl, Löffler, Kurt, Torres, Antoni. "Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation – The CIGMA study." Respiratory Medicine, vol. 109, no. 6, 2015, pp. 758-767. |
| Opal, S. M., van der Poll, T. "Endothelial barrier dysfunction in septic shock." J Intern Med, vol. 277, no. 3, 2015, pp. 277-293. |
| Opal, Steven. "Is Genomic Medicine Finally Coming of Age for the Diagnosis of Pneumonia?." Am J Respir Crit Care Med, vol. 192, no. 7, 2015, pp. 773-774. |
| Christaki E, Diza E, Giamarellos-Bourboulis EJ, Papadopoulou N, Pistiki A, Droggiti DI, Georgitsi M, Machova A, Lambrelli D, Malisiovas N, Nikolaidis P, Opal SM. "NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon-γ Production." Journal of immunology research, vol. 2015, 2015, pp. 532717. |
| Opal S, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, Chahin AB, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N. "PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS." Shock, vol. 45, no. 4, 2015, pp. 411-8. |
| Kalil, Andre C., Opal, Steven M. "Sepsis in the Severely Immunocompromised Patient." Current Infectious Disease Reports, vol. 17, no. 6, 2015. |
| Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, Jaton K, Giulieri S, Delaloye J, Opal S, Tracey K, van der Poll T, Pelfrene E. "Sepsis: a roadmap for future research." The Lancet Infectious Diseases, vol. 15, no. 5, 2015, pp. 581-614. |
| Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JH. "The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance." Am J Respir Crit Care Med, vol. 192, no. 11, 2015, pp. 1275-86. |
| Chahin A, Opal SM, Zorzopulos J, Jobes DV, Migdady Y, Yamamoto M, Parejo N, Palardy JE, Horn DL. "The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis." Antimicrobial Agents and Chemotherapy, vol. 59, no. 2, 2015, pp. 1225-9. |
| Fedson, David S., Jacobson, Jeffrey R., Rordam, Ole Martin, Opal, Steven M. "Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers." mBio, vol. 6, no. 3, 2015, pp. e00716-15. |
| Wittebole X, De Roock S, Opal SM. "A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens." Virulence, vol. 5, no. 1, 2014, pp. 226-35. |
| Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldawer LL, Demetriades D, Talving P, Schreiber M, Ham B, Cohen M, Opal S, Segalovich I, Maislin G, Kaempfer R, Shirvan A. "A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial." JAMA Surgery, vol. 149, no. 6, 2014, pp. 528-36. |
| Ramachandran G, Kaempfer R, Chung CS, Shirvan A, Chahin AB, Palardy JE, Parejo NA, Chen Y, Whitford M, Arad G, Hillman D, Shemesh R, Blackwelder W, Ayala A, Cross AS, Opal SM. "CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and Gram-negative bacterial peritonitis." The Journal of Infectious Diseases, vol. 211, no. 6, 2014, pp. 809-20. |
| Opal SM. "Dual inhibition of interleukin-1β and interleukin-18: a new treatment option for sepsis?." Am J Respir Crit Care Med, vol. 189, no. 3, 2014, pp. 242-4. |
| Heine HS, Louie A, Adamovicz JJ, Amemiya K, Fast RL, Miller L, Opal SM, Palardy J, Parejo NA, Sörgel F, Kinzig-Schippers M, Drusano GL. "Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague." Antimicrobial Agents and Chemotherapy, vol. 58, no. 6, 2014, pp. 3276-84. |
| Cross, Alan S., Karreman, Hubert J., Zhang, Lei, Rosenberg, Zeil, Opal, Steven M., Lees, Andrew. "Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum." Vaccine, vol. 32, no. 46, 2014, pp. 6107-6114. |
| Cunha CB, Opal SM. "Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia." Virulence, vol. 5, no. 6, 2014, pp. 650-4. |
| DeLeon TT, Chung HH, Opal SM, Dworkin JD. "Mycobacterium avium complex empyema in a patient with interferon gamma autoantibodies." Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, vol. 73, no. 9 Suppl 1, 2014, pp. 15-7. |
| Opal, Steven. "Number Needed to Treat—To Get Clinicians’ Attention*." Critical care medicine, vol. 42, no. 11, 2014, pp. 2444-2445. |
| Opal SM. "Significance of sialic acid in Klebsiella pneumoniae K1 capsules." Virulence, vol. 5, no. 6, 2014, pp. 648-9. |
| Wittebole X, Laterre PF, Opal SM. "Targeting toll-like receptors 4 intracellular domain to prevent ischemic liver disease: an innovative approach or just a futuristic dream?." Critical care medicine, vol. 42, no. 2, 2014, pp. 487-8. |
| Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. "The authors reply." Critical care medicine, vol. 42, no. 12, 2014, pp. e798-9. |
| Pop-Vicas A, Opal SM. "The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock." Virulence, vol. 5, no. 1, 2014, pp. 206-12. |
| Opal SM. "The current understanding of sepsis and research priorities for the future." Virulence, vol. 5, no. 1, 2014, pp. 1-3. |
| Opal SM, Fedson DS. "The dysfunctional host response to influenza A H7N9: a potential treatment option?." Critical Care, vol. 18, no. 2, 2014, pp. 135. |
| Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. "The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*." Critical care medicine, vol. 42, no. 7, 2014, pp. 1714-21. |
| Ramachandran G, Tulapurkar ME, Harris KM, Arad G, Shirvan A, Shemesh R, Detolla LJ, Benazzi C, Opal SM, Kaempfer R, Cross AS. "A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes." The Journal of Infectious Diseases, vol. 207, no. 12, 2013, pp. 1869-77. |
| Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, ACCESS Study Group. "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial." JAMA, vol. 309, no. 11, 2013, pp. 1154-62. |
| McCulloh R, Opal SM. "Human recombinant lactoferrin for sepsis: too good to be true?." Critical care medicine, vol. 41, no. 3, 2013, pp. 908-9. |
| Angione SL, Inde Z, Beck CM, Artenstein AW, Opal SM, Tripathi A. "Microdroplet sandwich real-time rt-PCR for detection of pandemic and seasonal influenza subtypes." PLoS ONE, vol. 8, no. 9, 2013, pp. e73497. |
| Pop-Vicas A, Opal SM. "Over-distension of the airways by mechanical ventilation in the elderly: adding insult to injury." Critical Care, vol. 17, no. 4, 2013, pp. 165. |
| Hurley JC, Opal SM. "Prognostic value of endotoxemia in patients with Gram-negative bacteremia is bacterial species dependent." Journal of innate immunity, vol. 5, no. 6, 2013, pp. 555-64. |
| Opal SM, LaRosa SP. "Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?." Am J Respir Crit Care Med, vol. 187, no. 10, 2013, pp. 1041-3. |
| Sim BT, Browne SK, Vigliani M, Zachary D, Rosen L, Holland SM, Opal SM. "Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies." Journal of clinical immunology, vol. 33, no. 6, 2013, pp. 1057-61. |
| Artenstein AW, Higgins TL, Opal SM. "Sepsis and scientific revolutions." Critical care medicine, vol. 41, no. 12, 2013, pp. 2770-2. |
| Vincent JL, Opal SM, Marshall JC, Tracey KJ. "Sepsis definitions - Authors' reply." The Lancet, vol. 381, no. 9885, 2013, pp. 2250. |
| Vincent JL, Opal SM, Marshall JC, Tracey KJ. "Sepsis definitions: time for change." The Lancet, vol. 381, no. 9868, 2013, pp. 774-5. |
| Wang J, Tai W, Angione SL, John AR, Opal SM, Artenstein AW, Tripathi A. "Subtyping clinical specimens of influenza A virus by use of a simple method to amplify RNA targets." Journal of clinical microbiology, vol. 51, no. 10, 2013, pp. 3324-30. |
| Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012." Critical care medicine, vol. 41, no. 2, 2013, pp. 580-637. |
| Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. "Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012." Intensive care medicine, vol. 39, no. 2, 2013, pp. 165-228. |
| Opal SM, Dellinger RP. "The authors reply." Critical care medicine, vol. 41, no. 12, 2013, pp. e488. |
| Opal SM, Dellinger RP. "The authors reply." Critical care medicine, vol. 41, no. 11, 2013, pp. e386-7. |
| Fedson DS, Opal SM. "The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threat." Human Vaccines & Immunotherapeutics, vol. 9, no. 5, 2013, pp. 977-86. |
| McCalla SE, Ong C, Sarma A, Opal SM, Artenstein AW, Tripathi A. "A simple method for amplifying RNA targets (SMART)." The Journal of molecular diagnostics : JMD, vol. 14, no. 4, 2012, pp. 328-35. |
| Opal SM. "ACP Journal Club. Review: Short-course antibiotics in hospital-acquired pneumonia do not affect mortality." Annals of Internal Medicine, vol. 156, no. 6, 2012, pp. JC3-13. |
| Larosa SP, Opal SM. "Immune aspects of sepsis and hope for new therapeutics." Current Infectious Disease Reports, vol. 14, no. 5, 2012, pp. 474-83. |
| Ong C, Tai W, Sarma A, Opal SM, Artenstein AW, Tripathi A. "Ligation with nucleic acid sequence-based amplification." The Journal of molecular diagnostics : JMD, vol. 14, no. 3, 2012, pp. 206-13. |
| Artenstein AW, Opal SM. "Novel approaches to the treatment of systemic anthrax." Clinical Infectious Diseases, vol. 54, no. 8, 2012, pp. 1148-61. |
| Christaki E, Lazaridis N, Opal SM. "Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?." Current opinion in infectious diseases, vol. 25, no. 3, 2012, pp. 304-11. |
| Fedson DS, Opal SM. "Research into transmissibility of influenza A H5N1: a practical response to the controversy." The Lancet Infectious Diseases, vol. 12, no. 5, 2012, pp. 364-5. |
| Cohen J, Opal S, Calandra T. "Sepsis studies need new direction." The Lancet Infectious Diseases, vol. 12, no. 7, 2012, pp. 503-5. |
| Ismail A, Pop-Vicas A, Opal S. "Spinal epidural abscess." Medicine and health, Rhode Island, vol. 95, no. 1, 2012, pp. 21-2. |
| Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K, Agarwal A, Covic L, Opal SM, Kuliopulos A. "A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis." EMBO molecular medicine, vol. 3, no. 7, 2011, pp. 370-84. |
| Christaki E, Opal SM, Keith JC Jr, Kessimian N, Palardy JE, Parejo NA, Tan XY, Piche-Nicholas N, Tchistiakova L, Vlasuk GP, Shields KM, Feldman JL, Lavallie ER, Arai M, Mounts W, Pittman DD. "A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia." Shock, vol. 35, no. 5, 2011, pp. 492-8. |
| LaRosa SP, Opal SM. "Biomarkers: the future." Critical Care Clinics, vol. 27, no. 2, 2011, pp. 407-19. |
| Opal SM. "Endotoxemia before and after surgical repair for congenital heart disease." Am J Respir Crit Care Med, vol. 184, no. 11, 2011, pp. 1223-4. |
| Delsesto D, Opal SM. "Future perspectives on regulating pro-and anti-inflammatory responses in sepsis." Contributions to microbiology, vol. 17, 2011, pp. 137-56. |
| Opal SM. "Immunologic alterations and the pathogenesis of organ failure in the ICU." Seminars in Respiratory and Critical Care Medicine, vol. 32, no. 5, 2011, pp. 569-80. |
| Christaki E, Anyfanti P, Opal SM. "Immunomodulatory therapy for sepsis: an update." Expert review of anti-infective therapy, vol. 9, no. 11, 2011, pp. 1013-33. |
| Kalil AC, LaRosa SP, Gogate J, Lynn M, Opal SM, Eritoran Sepsis Study Group. "Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis." Shock, vol. 36, no. 4, 2011, pp. 327-31. |
| Opal SM, Lim YP, Cristofaro P, Artenstein AW, Kessimian N, Delsesto D, Parejo N, Palardy JE, Siryaporn E. "Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection." Shock, vol. 35, no. 1, 2011, pp. 42-4. |
| Artenstein AW, Opal SM. "Proprotein convertases in health and disease." New England Journal of Medicine, vol. 365, no. 26, 2011, pp. 2507-18. |
| Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S, CAPTIVATE Trial Group. "Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial." Am J Respir Crit Care Med, vol. 183, no. 11, 2011, pp. 1561-8. |
| Opal SM. "The evolution of the understanding of sepsis, infection, and the host response: a brief history." Critical care nursing clinics of North America, vol. 23, no. 1, 2011, pp. 1-27. |
| Kerby MB, Sarma AA, Patel MS, Artenstein AW, Opal SM, Tripathi A. "The PIRO concept: I is for infection." Applied biochemistry and biotechnology, vol. 7, no. 3, 2011, pp. 497-513. |
| Christ-Crain M, Opal SM. "Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia." Critical Care, vol. 14, no. 1, 2010, pp. 203. |
| Al-Qadi MO, Al-Alwan A, Opal SM, Cillley B, Silverblatt FJ. "Community acquired pneumonia." Medicine and health, Rhode Island, vol. 93, no. 7, 2010, pp. 196-200. |
| Gregory SH, Chen WH, Mott S, Palardy JE, Parejo NA, Heninger S, Anderson CA, Artenstein AW, Opal SM, Cross AS. "Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4." Vaccine, vol. 28, no. 16, 2010, pp. 2908-15. |
| Opal SM. "Endotoxin desynchronizes biological clocks." Critical care medicine, vol. 38, no. 3, 2010, pp. 977-8. |
| Opal SM. "Endotoxins and other sepsis triggers." Contributions to nephrology, vol. 167, 2010, pp. 14-24. |
| Christaki E, Opal SM, Keith JC Jr, Kessinian N, Palardy JE, Parejo NA, Lavallie E, Racie L, Mounts W, Malamas MS, Mewshaw RE, Harris HA, Vlasuk GP. "Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study." The Journal of Infectious Diseases, vol. 201, no. 8, 2010, pp. 1250-7. |
| Hotchkiss RS, Opal S. "Immunotherapy for sepsis--a new approach against an ancient foe." New England Journal of Medicine, vol. 363, no. 1, 2010, pp. 87-9. |
| Opal SM. "New perspectives on immunomodulatory therapy for bacteraemia and sepsis." International journal of antimicrobial agents, vol. 36 Suppl 2, 2010, pp. S70-3. |
| Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM, Eritoran Sepsis Study Group. "Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis." Critical care medicine, vol. 38, no. 1, 2010, pp. 72-83. |
| Vincent JL, Opal SM, Marshall JC. "Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions." Critical care medicine, vol. 38, no. 1, 2010, pp. 283-7. |
| Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, Poole L, Wunderink RG. "A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia." Critical Care, vol. 13, no. 2, 2009, pp. R36. |
| Opal SM, Calandra T. "Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients?." JAMA, vol. 302, no. 21, 2009, pp. 2367-8. |
| Opal SM. "Coming soon to an ICU near you: severe pandemic influenza in ICU patients in Spain." Critical Care, vol. 13, no. 5, 2009, pp. 196. |
| Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J, Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. "Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial." Critical care medicine, vol. 37, no. 11, 2009, pp. 2929-38. |
| Cinel I, Opal SM. "Molecular biology of inflammation and sepsis: a primer." Critical care medicine, vol. 37, no. 1, 2009, pp. 291-304. |
| van der Poll T, Opal SM. "Pathogenesis, treatment, and prevention of pneumococcal pneumonia." The Lancet, vol. 374, no. 9700, 2009, pp. 1543-56. |
| Opal SM. "Swine flu, pandemics, and critical care." Critical Care, vol. 13, no. 3, 2009, pp. 146. |
| Opal SM. "The evolution of the understanding of sepsis, infection, and the host response: a brief history." Critical Care Clinics, vol. 25, no. 4, 2009, pp. 637-63, vii. |
| Opal SM, Patrozou E. "Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?." Critical care medicine, vol. 37, no. 1 Suppl, 2009, pp. S10-5. |
| Opal SM, LaRosa SP. "Year in review 2008: Critical Care--sepsis." Critical Care, vol. 13, no. 5, 2009, pp. 224. |
| Asad S, Opal SM. "Bench-to-bedside review: Quorum sensing and the role of cell-to-cell communication during invasive bacterial infection." Critical Care, vol. 12, no. 6, 2008, pp. 236. |
| Kerby MB, Freeman S, Prachanronarong K, Artenstein AW, Opal SM, Tripathi A. "Direct sequence detection of structured h5 influenza viral RNA." The Journal of molecular diagnostics : JMD, vol. 10, no. 3, 2008, pp. 225-35. |
| van der Poll T, Opal SM. "Host-pathogen interactions in sepsis." The Lancet Infectious Diseases, vol. 8, no. 1, 2008, pp. 32-43. |
| Christaki E, Opal SM. "Is the mortality rate for septic shock really decreasing?." Current Opinion in Critical Care, vol. 14, no. 5, 2008, pp. 580-6. |
| Patrozou E, Opal S. "Scurvy masquerading as infectious cellulitis [corrected]." Internal medicine journal, vol. 38, no. 6, 2008, pp. 452-3. |
| LaRosa SP, Opal SM. "Sepsis strategies in development." Clinics in Chest Medicine, vol. 29, no. 4, 2008, pp. 735-47, x-xi. |
| Carlet J, Cohen J, Calandra T, Opal SM, Masur H. "Sepsis: time to reconsider the concept." Critical care medicine, vol. 36, no. 3, 2008, pp. 964-6. |
| Aarts MA, Brun-Buisson C, Cook DJ, Kumar A, Opal S, Rocker G, Smith T, Vincent JL, Marshall JC. "Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome?." Intensive care medicine, vol. 33, no. 8, 2007, pp. 1369-78. |
| Lutterloh EC, Opal SM. "Antibodies against RAGE in sepsis and inflammation: implications for therapy." Expert opinion on pharmacotherapy, vol. 8, no. 9, 2007, pp. 1193-6. |
| Opal SM. "Can we RESOLVE the treatment of sepsis?." The Lancet, vol. 369, no. 9564, 2007, pp. 803-4. |
| Opal SM. "Communal living by bacteria and the pathogenesis of urinary tract infections." PLOS Medicine, vol. 4, no. 12, 2007, pp. e349. |
| Opal SM. "Endotoxin and cytokine detection systems as biomarkers for sepsis-induced renal injury." Contributions to nephrology, vol. 156, 2007, pp. 220-6. |
| Opal SM, Lim YP, Siryaporn E, Moldawer LL, Pribble JP, Palardy JE, Souza S. "Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis." Critical care medicine, vol. 35, no. 2, 2007, pp. 387-92. |
| Opal SM. "The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis." International journal of medical microbiology : IJMM, vol. 297, no. 5, 2007, pp. 365-77. |
| Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N. "Unusual nosocomial pathogens." Critical Care, vol. 3, no. 4, 2007, pp. 883-99. |
| Wiedermann CJ, Keinecke HO, Jürs M, Opal SM. "Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants." Shock, vol. 25, no. 6, 2006, pp. 657-8. |
| Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM, KyberSept investigators. "Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin." Thrombosis and haemostasis, vol. 95, no. 5, 2006, pp. 850-6. |
| Levi M, Opal SM. "Coagulation abnormalities in critically ill patients." Critical Care, vol. 10, no. 4, 2006, pp. 222. |
| LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr. "Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei." International Journal of Infectious Diseases, vol. 10, no. 1, 2006, pp. 25-31. |
| Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM, KyberSept Investigators. "High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety." Critical care medicine, vol. 34, no. 2, 2006, pp. 285-92. |
| Cristofaro P, Opal SM. "Role of Toll-like receptors in infection and immunity: clinical implications." Drugs, vol. 66, no. 1, 2006, pp. 15-29. |
| Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, Osman J, Trenholme G, Opal SM, Goldfarb R, Parrillo JE. "The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels." The Journal of Infectious Diseases, vol. 193, no. 2, 2006, pp. 251-8. |
| Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM, KyberSept investigators. "Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation." Journal of thrombosis and haemostasis : JTH, vol. 4, no. 1, 2006, pp. 90-7. |
| Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC Jr, Harris HA. "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock." Critical care medicine, vol. 34, no. 8, 2006, pp. 2188-93. |
| Opal SM, Palardy JE, Chen WH, Parejo NA, Bhattacharjee AK, Cross AS. "Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms." The Journal of Infectious Diseases, vol. 192, no. 12, 2005, pp. 2074-80. |
| Opal SM. "Concept of PIRO as a new conceptual framework to understand sepsis." Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, vol. 6, no. 3 Suppl, 2005, pp. S55-60. |
| Artenstein AW, Opal JM, Opal SM, Tramont EC, Peter G, Russell PK. "History of U.S. military contributions to the study of vaccines against infectious diseases." Military Medicine, vol. 170, no. 4 Suppl, 2005, pp. 3-11. |
| Girard TD, Opal SM, Ely EW. "Insights into severe sepsis in older patients: from epidemiology to evidence-based management." Clinical Infectious Diseases, vol. 40, no. 5, 2005, pp. 719-27. |
| Opal SM, Artenstein AW, Cristofaro PA, Jhung JW, Palardy JE, Parejo NA, Lim YP. "Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication." Infection and Immunity, vol. 73, no. 8, 2005, pp. 5101-5. |
| Thompson AE, Marshall JC, Opal SM. "Intraabdominal infections in infants and children: descriptions and definitions." Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, vol. 6, no. 3 Suppl, 2005, pp. S30-5. |
| Marshall JC, Deitch E, Moldawer LL, Opal S, Redl H, van der Poll T. "Preclinical models of shock and sepsis: what can they tell us?." Shock, vol. 24 Suppl 1, 2005, pp. 1-6. |
| Opal SM, Palardy JE, Cristofaro P, Parejo N, Jhung JW, Keith JC Jr, Chippari S, Caggiano TJ, Steffan RJ, Chadwick CC, Harnish DC. "The activity of pathway-selective estrogen receptor ligands in experimental septic shock." Shock, vol. 24, no. 6, 2005, pp. 535-40. |
| Opal SM, Girard TD, Ely EW. "The immunopathogenesis of sepsis in elderly patients." Clinical Infectious Diseases, vol. 41 Suppl 7, 2005, pp. S504-12. |
| Opal SM, Cross AS. "The use of immunocompromised animals as models for human septic shock." Shock, vol. 24 Suppl 1, 2005, pp. 64-70. |
| LaRosa SP, Opal SM. "Tissue factor pathway inhibitor and antithrombin trial results." Critical Care Clinics, vol. 21, no. 3, 2005, pp. 433-48. |
| Glück T, Opal SM. "Advances in sepsis therapy." Drugs, vol. 64, no. 8, 2004, pp. 837-59. |
| Reinhart K, Glück T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J, Opal S, Moldawer LL, Axtelle T, Turner T, Souza S, Pribble J. "CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)." Critical care medicine, vol. 32, no. 5, 2004, pp. 1100-8. |
| Artenstein AW, Opal SM, Cristofaro P, Palardy JE, Parejo NA, Green MD, Jhung JW. "Chloroquine enhances survival in Bacillus anthracis intoxication." The Journal of Infectious Diseases, vol. 190, no. 9, 2004, pp. 1655-60. |
| Amaral A, Opal SM, Vincent JL. "Coagulation in sepsis." Intensive care medicine, vol. 30, no. 6, 2004, pp. 1032-40. |
| Cross AS, Opal S, Cook P, Drabick J, Bhattacharjee A. "Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis." Vaccine, vol. 22, no. 7, 2004, pp. 812-7. |
| Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A, MEDIC study. "Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study." The Journal of Infectious Diseases, vol. 190, no. 3, 2004, pp. 527-34. |
| Cohen J, Cristofaro P, Carlet J, Opal S. "New method of classifying infections in critically ill patients." Critical care medicine, vol. 32, no. 7, 2004, pp. 1510-26. |
| Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. "Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial." Critical care medicine, vol. 32, no. 2, 2004, pp. 332-41. |
| Gea-Banacloche JC, Opal SM, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C. "Sepsis associated with immunosuppressive medications: an evidence-based review." Critical care medicine, vol. 32, no. 11 Suppl, 2004, pp. S578-90. |
| Opal SM. "The nexus between systemic inflammation and disordered coagulation in sepsis." Journal of Endotoxin Research, vol. 10, no. 2, 2004, pp. 125-9. |
| Opal SM. "Unintended bias, clinical trial results, and the heparin post hoc crossover fallacy." Critical care medicine, vol. 32, no. 3, 2004, pp. 874-5. |
| Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, International Sepsis Definitions Conference. "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference." Intensive care medicine, vol. 29, no. 4, 2003, pp. 530-8. |
| Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS. "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference." Critical care medicine, vol. 31, no. 4, 2003, pp. 1250-6. |
| Opal S. "[Severe sepsis: perspectives]." Annales francaises d'anesthesie et de reanimation, vol. 22 Spec No 1, 2003, pp. 31-3. |
| Opal S. "[The FDA's questions]." Annales francaises d'anesthesie et de reanimation, vol. 22 Spec No 1, 2003, pp. 20-2. |
| Cross AS, Opal SM. "A new paradigm for the treatment of sepsis: is it time to consider combination therapy?." Annals of Internal Medicine, vol. 138, no. 6, 2003, pp. 502-5. |
| Opal SM, Esmon CT. "Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis." Critical Care, vol. 7, no. 1, 2003, pp. 23-38. |
| Opal SM. "Clinical trial design and outcomes in patients with severe sepsis." Shock, vol. 20, no. 4, 2003, pp. 295-302. |
| Lim YP, Bendelja K, Opal SM, Siryaporn E, Hixson DC, Palardy JE. "Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis." The Journal of Infectious Diseases, vol. 188, no. 6, 2003, pp. 919-26. |
| Opal SM. "Corticosteroids for patients with septic shock." JAMA, vol. 289, no. 1, 2003, pp. 41-2; author reply 43-4. |
| Opal SM, Palardy JE, Parejo N, Jasman RL. "Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia." Critical care medicine, vol. 31, no. 3, 2003, pp. 929-32. |
| Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, OPTIMIST Trial Study Group. "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial." JAMA, vol. 290, no. 2, 2003, pp. 238-47. |
| Opal SM, Glück T. "Endotoxin as a drug target." Critical care medicine, vol. 31, no. 1 Suppl, 2003, pp. S57-64. |
| Opal SM. "Interactions between coagulation and inflammation." Scandinavian journal of infectious diseases, vol. 35, no. 9, 2003, pp. 545-54. |
| Opal SM, Keith JC Jr, Jhung J, Palardy JE, Parejo N, Marchese E, Maganti V. "Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis." The Journal of Infectious Diseases, vol. 187, no. 1, 2003, pp. 70-6. |
| Cross AS, Opal SM, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattacharjee AK. "Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects." Vaccine, vol. 21, no. 31, 2003, pp. 4576-87. |
| Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J, Pafase ARDS Prevention Study Group. "Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial." Critical care medicine, vol. 31, no. 6, 2003, pp. 1612-9. |
| Opal SM. "Severe sepsis and septic shock: defining the clinical problem." Scandinavian journal of infectious diseases, vol. 35, no. 9, 2003, pp. 529-34. |
| Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR. "Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)." Clinical Infectious Diseases, vol. 37, no. 1, 2003, pp. 50-8. |
| Cristofaro P, Opal SM. "The Toll-like receptors and their role in septic shock." Expert Opinion on Therapeutic Targets, vol. 7, no. 5, 2003, pp. 603-12. |
| Opal SM, Kessler CM, Roemisch J, Knaub S. "Antithrombin, heparin, and heparan sulfate." Critical care medicine, vol. 30, no. 5 Suppl, 2002, pp. S325-31. |
| Opal SM, Huber CE. "Bench-to-bedside review: Toll-like receptors and their role in septic shock." Critical Care, vol. 6, no. 2, 2002, pp. 125-36. |
| Artenstein AW, Neill MA, Opal SM. "Bioterrorism and physicians." Annals of Internal Medicine, vol. 137, no. 7, 2002, pp. 626. |
| Artenstein AW, Neill MA, Opal SM. "Bioterrorism and physicians." Medicine and health, Rhode Island, vol. 85, no. 2, 2002, pp. 74-6. |
| Opal SM. "Insights into the immune dysfunction associated with thermal injury." Critical care medicine, vol. 30, no. 7, 2002, pp. 1651-2. |
| Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S. "Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]." Critical Care, vol. 6, no. 4, 2002, pp. 349-56. |
| Manalo R, Mirza H, Opal S. "Streptococcus pyogenes tuboovarian abscess: a potential sexually transmitted disease?." Sexually Transmitted Diseases, vol. 29, no. 10, 2002, pp. 606-7. |
| Opal SM. "The clinical relevance of endotoxin in human sepsis: a critical analysis." Journal of Endotoxin Research, vol. 8, no. 6, 2002, pp. 473-6. |
| Cross AS, Opal SM, Warren HS, Palardy JE, Glaser K, Parejo NA, Bhattacharjee AK. "Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis." The Journal of Infectious Diseases, vol. 183, no. 7, 2001, pp. 1079-86. |
| Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group. "Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial." JAMA, vol. 286, no. 15, 2001, pp. 1869-78. |
| Opal SM. "Clinical impact of novel anticoagulation strategies in sepsis." Current Opinion in Critical Care, vol. 7, no. 5, 2001, pp. 347-53. |
| Opal SM, Sypek JP, Keith JC Jr, Schaub RG, Palardy JE, Parejo NA. "Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection." Shock, vol. 15, no. 4, 2001, pp. 285-90. |
| Opal SM, Palardy JE, Parejo N, Morrison DC. "Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis." Journal of Endotoxin Research, vol. 7, no. 1, 2001, pp. 35-8. |
| Cohen J, Guyatt G, Bernard GR, Calandra T, Cook D, Elbourne D, Marshall J, Nunn A, Opal S, UK Medical Research Council International Working Party. "New strategies for clinical trials in patients with sepsis and septic shock." Critical care medicine, vol. 29, no. 4, 2001, pp. 880-6. |
| Opal SM. "Protein C levels in severe sepsis." Chest, vol. 120, no. 3, 2001, pp. 699-701. |
| Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, van der Poll T. "Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia." Kidney International, vol. 59, no. 6, 2001, pp. 2054-61. |
| Opal SM, Palardy JE, Parejo NA, Creasey AA. "The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis." Critical care medicine, vol. 29, no. 1, 2001, pp. 13-7. |
| Luchi M, Morrison DC, Opal S, Yoneda K, Slotman G, Chambers H, Wiesenfeld H, Lemke J, Ryan JL, Horn D. "A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group." Journal of Endotoxin Research, vol. 6, no. 1, 2000, pp. 25-31. |
| Opal SM, DePalo VA. "Anti-inflammatory cytokines." Chest, vol. 117, no. 4, 2000, pp. 1162-72. |
| Olszyna DP, Opal SM, Prins JM, Horn DL, Speelman P, van Deventer SJ, van der Poll T. "Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis." The Journal of Infectious Diseases, vol. 182, no. 6, 2000, pp. 1731-7. |
| Abraham E, Matthay MA, Dinarello CA, Vincent JL, Cohen J, Opal SM, Glauser M, Parsons P, Fisher CJ Jr, Repine JE. "Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation." Critical care medicine, vol. 28, no. 1, 2000, pp. 232-5. |
| Glück T, Opal S, Alattar-Mantis J, Weitzel T, Lode H, Schölmerich J. "Differences between American and German medical students and physicians in knowledge of infectious diseases." European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, vol. 19, no. 11, 2000, pp. 868-70. |
| Simpson AJ, Opal SM, Angus BJ, Prins JM, Palardy JE, Parejo NA, Chaowagul W, White NJ. "Differential antibiotic-induced endotoxin release in severe melioidosis." The Journal of Infectious Diseases, vol. 181, no. 3, 2000, pp. 1014-9. |
| Opal SM. "Hemofiltration-absorption systems for the treatment of experimental sepsis: is it possible to remove the "evil humors" responsible for septic shock?." Critical care medicine, vol. 28, no. 5, 2000, pp. 1681-2. |
| Opal SM. "Phylogenetic and functional relationships between coagulation and the innate immune response." Critical care medicine, vol. 28, no. 9 Suppl, 2000, pp. S77-80. |
| Opal SM, Keith JC, Palardy JE, Parejo N. "Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection." The Journal of Infectious Diseases, vol. 181, no. 2, 2000, pp. 754-6. |
| Opal S, Thijs L, Cavaillon JM, Cohen J, Fourrier F. "Roundtable I: relationships between coagulation and inflammatory processes." Critical care medicine, vol. 28, no. 9 Suppl, 2000, pp. S81-2. |
| Opal SM, Huber CE. "The role of interleukin-10 in critical illness." Current opinion in infectious diseases, vol. 13, no. 3, 2000, pp. 221-226. |
| Opal SM. "Therapeutic rationale for antithrombin III in sepsis." Critical care medicine, vol. 28, no. 9 Suppl, 2000, pp. S34-7. |
| Horn DL, Morrison DC, Opal SM, Silverstein R, Visvanathan K, Zabriskie JB. "What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium." Clinical Infectious Diseases, vol. 31, no. 4, 2000, pp. 851-8. |
| Opal SM, Jhung JW, Keith JC Jr, Goldman SJ, Palardy JE, Parejo NA. "Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis." Blood, vol. 93, no. 10, 1999, pp. 3467-72. |
| Opal SM, Cohen J. "Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?." Critical care medicine, vol. 27, no. 8, 1999, pp. 1608-16. |
| Opal SM, Cross AS. "Clinical trials for severe sepsis. Past failures, and future hopes." Infectious disease clinics of North America, vol. 13, no. 2, 1999, pp. 285-97, vii. |
| Cross AS, Opal SM, Bhattacharjee AK, Donta ST, Peduzzi PN, Fürer E, Que JU, Cryz SJ. "Immunotherapy of sepsis: flawed concept or faulty implementation?." Vaccine, vol. 17 Suppl 2, 1999, pp. S13-21. |
| Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH. "Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock." The Journal of Infectious Diseases, vol. 180, no. 5, 1999, pp. 1584-9. |
| Opal SM. "Selenium replacement in severe systemic inflammatory response syndrome." Critical care medicine, vol. 27, no. 9, 1999, pp. 2042-3. |
| Opal SM. "Tumor necrosis factor receptor expression on inflammatory cells in sepsis." Critical care medicine, vol. 27, no. 2, 1999, pp. 240-1. |
| Opal SM, Yu RL Jr. "Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions." Drugs, vol. 55, no. 4, 1998, pp. 497-508. |
| Opal SM, Wherry JC, Grint P. "Interleukin-10: potential benefits and possible risks in clinical infectious diseases." Clinical Infectious Diseases, vol. 27, no. 6, 1998, pp. 1497-507. |
| Opal SM, Jhung JW, Keith JC Jr, Palardy JE, Parejo NA, Young LD, Bhattacharjee A. "Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals." The Journal of Infectious Diseases, vol. 178, no. 4, 1998, pp. 1205-8. |
| Opal SM. "The uncertain value of the definition for SIRS. Systemic inflammatory response syndrome." Chest, vol. 113, no. 6, 1998, pp. 1442-3. |
| Horn DL, Zabriskie JB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA, Gotschlich E, Kaplan EL, McCarty M, Opal SM, Roberts RB, Tomasz A, Wachtfogel Y. "Why have group A streptococci remained susceptible to penicillin? Report on a symposium." Clinical Infectious Diseases, vol. 26, no. 6, 1998, pp. 1341-5. |
| Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA. "Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection." Journal of Experimental Medicine, vol. 185, no. 7, 1997, pp. 1185-92. |
| Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. "Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group." Critical care medicine, vol. 25, no. 7, 1997, pp. 1115-24. |
| Orange JS, Salazar-Mather TP, Opal SM, Biron CA. "Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection." Journal of Virology, vol. 71, no. 12, 1997, pp. 9248-58. |
| Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS. "A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia." The Journal of Infectious Diseases, vol. 173, no. 5, 1996, pp. 1157-63. |
| Horn DL, Opal SM, Lomastro E. "Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis." Scandinavian journal of infectious diseases. Supplementum, vol. 101, 1996, pp. 9-13. |
| Opal SM. "Infectious disease challenges in the 1990's." Medicine and health, Rhode Island, vol. 79, no. 3, 1996, pp. 100-9. |
| Opal SM, Cross AS, Jhung JW, Young LD, Palardy JE, Parejo NA, Donsky C. "Potential hazards of combination immunotherapy in the treatment of experimental septic shock." The Journal of Infectious Diseases, vol. 173, no. 6, 1996, pp. 1415-21. |
| Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. "Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group." New England Journal of Medicine, vol. 334, no. 26, 1996, pp. 1697-702. |
| Opal SM, Palardy JE, Jhung JW, Donsky C, Romulo RL, Parejo N, Marra MN. "Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis." Antimicrobial Agents and Chemotherapy, vol. 39, no. 12, 1995, pp. 2813-5. |
| Coronado BE, Opal SM, Yoburn DC. "Antibiotic-induced D-lactic acidosis." Annals of Internal Medicine, vol. 122, no. 11, 1995, pp. 839-42. |
| Rice SK, Heinl RE, Thornton LL, Opal SM. "Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis." Clinical Infectious Diseases, vol. 20, no. 4, 1995, pp. 931-7. |
| Meyerhoff A, Renzi RM, Wehbe T, Opal SM. "Fatal clostridial sepsis in a previously healthy woman." Clinical Infectious Diseases, vol. 20, no. 4, 1995, pp. 1066-7. |
| Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA. "Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids." Journal of Experimental Medicine, vol. 181, no. 3, 1995, pp. 901-14. |
| Bhattacharjee AK, Opal SM, Palardy JE, Drabick JJ, Collins H, Taylor R, Cotton A, Cross AS. "Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis." The Journal of Infectious Diseases, vol. 170, no. 3, 1994, pp. 622-9. |
| Pololi LH, Coletta EM, Kern DG, Davis S, Kiessling LS, Garber CE, Entin EJ, Opal SM, Rakowski W. "Developing a competency-based preventive medicine curriculum for medical schools." American Journal of Preventive Medicine, vol. 10, no. 4, 1994, pp. 240-4. |
| Suitters AJ, Foulkes R, Opal SM, Palardy JE, Emtage JS, Rolfe M, Stephens S, Morgan A, Holt AR, Chaplin LC. "Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock." Journal of Experimental Medicine, vol. 179, no. 3, 1994, pp. 849-56. |
| Fisher CJ Jr, Marra MN, Palardy JE, Marchbanks CR, Scott RW, Opal SM. "Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study." Critical care medicine, vol. 22, no. 4, 1994, pp. 553-8. |
| Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA, IL-1RA Sepsis Syndrome Study Group. "Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial." Critical care medicine, vol. 22, no. 1, 1994, pp. 12-21. |
| Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM. "Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis." New England Journal of Medicine, vol. 330, no. 17, 1994, pp. 1241. |
| Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Romulo RL, Fortna S, Medeiros AA. "Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance." Journal of clinical microbiology, vol. 32, no. 5, 1994, pp. 1148-53. |
| Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL. "Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group." JAMA, vol. 271, no. 23, 1994, pp. 1836-43. |
| Opal SM, Palardy JE, Marra MN, Fisher CJ Jr, McKelligon BM, Scott RW. "Relative concentrations of endotoxin-binding proteins in body fluids during infection." The Lancet, vol. 344, no. 8920, 1994, pp. 429-31. |
| Fisher CJ Jr, Opal SM, Lowry SF, Sadoff JC, LaBrecque JF, Donovan HC, Lookabaugh JL, Lemke J, Pribble JP, Stromatt SC. "Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis." Circulatory shock, vol. 44, no. 1, 1994, pp. 1-8. |
| Horn DL, Hewlett D Jr, Haas WH, Butler WR, Alfalla C, Tan E, Levine A, Nayak A, Opal SM. "Superinfection with rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis in three patients with AIDS: confirmation by polymerase chain reaction fingerprinting." Annals of Internal Medicine, vol. 121, no. 2, 1994, pp. 115-6. |
| Cross AS, Opal SM, Sadoff JC, Gemski P. "Choice of bacteria in animal models of sepsis." Infection and Immunity, vol. 61, no. 7, 1993, pp. 2741-7. |
| Romulo RL, Palardy JE, Opal SM. "Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis." The Journal of Infectious Diseases, vol. 167, no. 1, 1993, pp. 126-30. |
| Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL. "Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group." Critical care medicine, vol. 21, no. 3, 1993, pp. 318-27. |
| Richards MS, Rittman M, Gilbert TT, Opal SM, DeBuono BA, Neill RJ, Gemski P. "Investigation of a staphylococcal food poisoning outbreak in a centralized school lunch program." public health reports, vol. 108, no. 6, 1993, pp. 765-71. |
| Horn DL, Hewlett D Jr, Peterson S, Sabido D, Opal SM. "RISE-resistant tuberculous meningitis in AIDS patient." The Lancet, vol. 341, no. 8838, 1993, pp. 177-8. |
| Boyce JM, Opal SM, Potter-Bynoe G, Medeiros AA. "Spread of methicillin-resistant Staphylococcus aureus in a hospital after exposure to a health care worker with chronic sinusitis." Clinical Infectious Diseases, vol. 17, no. 3, 1993, pp. 496-504. |
| Knaus WA, Harrell FE, Fisher CJ Jr, Wagner DP, Opal SM, Sadoff JC, Draper EA, Walawander CA, Conboy K, Grasela TH. "The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis." JAMA, vol. 270, no. 10, 1993, pp. 1233-41. |
| Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. "The efficacy of combination immunotherapy in experimental Pseudomonas sepsis." The Journal of Infectious Diseases, vol. 167, no. 1, 1993, pp. 112-8. |
| Boyce JM, Opal SM, Potter-Bynoe G, LaForge RG, Zervos MJ, Furtado G, Victor G, Medeiros AA. "Emergence and nosocomial transmission of ampicillin-resistant enterococci." Antimicrobial Agents and Chemotherapy, vol. 36, no. 5, 1992, pp. 1032-9. |
| Cross AS, Opal SM. "Group B streptococcal sepsis." JAMA, vol. 268, no. 19, 1992, pp. 2651. |
| Kim KS, Wass CA, Cross AS, Opal SM. "Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat." Lymphokine and cytokine research, vol. 11, no. 6, 1992, pp. 293-8. |
| Heelan JS, Opal SM, Brissette E, Donahue M. "The impact of converting to a biphasic blood-culture system on the overall cost and the incidence of pseudobacteremia." Diagnostic microbiology and infectious disease, vol. 15, no. 1, 1992, pp. 5-11. |
| Opal SM, Cross AS, Sadoff JC, Collins HH, Kelly NM, Victor GH, Palardy JE, Bodmer MW. "Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis." Journal of Clinical Investigation, vol. 88, no. 3, 1991, pp. 885-90. |
| Neill MA, Opal SM, Heelan J, Giusti R, Cassidy JE, White R, Mayer KH. "Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers." Annals of Internal Medicine, vol. 114, no. 3, 1991, pp. 195-9. |
| Wiest PM, Opal SM, Romulo RL, Olds GR. "Malaria in travelers in Rhode Island: a review of 26 cases." The American Journal of Medicine, vol. 91, no. 1, 1991, pp. 30-6. |
| Victor GH, Opal SM. "Spontaneous bacterial peritonitis: Analysis of treatment and outcome." The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, vol. 2, no. 4, 1991, pp. 147-54. |
| Boyce JM, Potter-Bynoe G, Opal SM, Dziobek L, Medeiros AA. "A common-source outbreak of Staphylococcus epidermidis infections among patients undergoing cardiac surgery." The Journal of Infectious Diseases, vol. 161, no. 3, 1990, pp. 493-9. |
| Opal SM, Cross AS, Gemski P, Lyhte LW. "Aerobactin and alpha-hemolysin as virulence determinants in Escherichia coli isolated from human blood, urine, and stool." The Journal of Infectious Diseases, vol. 161, no. 4, 1990, pp. 794-6. |
| Opal SM, Cross AS, Kelly NM, Sadoff JC, Bodmer MW, Palardy JE, Victor GH. "Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa." The Journal of Infectious Diseases, vol. 161, no. 6, 1990, pp. 1148-52. |
| Opal SM, Mayer KH, Stenberg MJ, Blazek JE, Mikolich DJ, Dickensheets DL, Lyhte LW, Trudel RR, Musser JM. "Frequent acquisition of multiple strains of methicillin-resistant Staphylococcus aureus by healthcare workers in an endemic hospital environment." Infection Control & Hospital Epidemiology, vol. 11, no. 9, 1990, pp. 479-85. |
| Wiest PM, Opal SM, Olds GR. "Malaria: the deadly threat from overseas." Rhode Island medical journal (2013), vol. 73, no. 5, 1990, pp. 207-12. |
| Emgushov RT, Opal SM. "Recent advances in infectious diseases." Rhode Island medical journal (2013), vol. 73, no. 11, 1990, pp. 517-23. |
| Romulo RL, Wiest PM, Opal SM, Olds GR. "Travel to developing countries: pre-departure medical advice." Rhode Island medical journal (2013), vol. 73, no. 5, 1990, pp. 181-7. |
| Opal SM, Wiest PM, Olds GR. "Traveler's diarrhea: methods of prevention and treatment." Rhode Island medical journal (2013), vol. 73, no. 5, 1990, pp. 199-204. |
| Debuono BA, Opal SM, Sarafian SK, Lyhte LW. "Analysis of an outbreak of penicillinase-producing Neisseria gonorrhoeae in Rhode Island, 1987." Journal of clinical microbiology, vol. 27, no. 9, 1989, pp. 2125-7. |
| Cronan JJ, Marcello A, Horn DL, Robinson A, Dorfman GS, Opal S. "Antibiotics and nephrostomy tube care: preliminary observations. Part I. Bacteriuria." Radiology, vol. 172, no. 3 Pt 2, 1989, pp. 1041-2. |
| Cronan JJ, Horn DL, Marcello A, Robinson A, Paolella LP, Lambiase RE, Haas RA, Opal S, Dorfman GS. "Antibiotics and nephrostomy tube care: preliminary observations. Part II. Bacteremia." Radiology, vol. 172, no. 3 Pt 2, 1989, pp. 1043-5. |
| Opal SM, Mayer KH, Roland F, Brondum J, Heelan J, Lyhte L. "Investigation of a food-borne outbreak of salmonellosis among hospital employees." American journal of infection control, vol. 17, no. 3, 1989, pp. 141-7. |
| Opal SM, Boyce JM, Medeiros AA, Mayer KH, Lyhte LW. "Modification of homogeneous resistance in a methicillin-resistant strain of Staphylococcus aureus by acquisition of a beta-lactamase encoding plasmid." Journal of Antimicrobial Chemotherapy, vol. 23, no. 3, 1989, pp. 315-25. |
| Collins HH, Cross AS, Dobek A, Opal SM, McClain JB, Sadoff JC. "Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa." The Journal of Infectious Diseases, vol. 159, no. 6, 1989, pp. 1073-82. |
| Victor G, Branley J, Opal SM, Mayer KH. "Pyomyositis in a patient with the acquired immunodeficiency syndrome." Arch Intern Med, vol. 149, no. 3, 1989, pp. 705, 709. |
| Bradburne RM, Ettensohn DB, Opal SM, McCool FD. "Relapse of Pneumocystis carinii pneumonia in the upper lobes during aerosol pentamidine prophylaxis." Thorax, vol. 44, no. 7, 1989, pp. 591-3. |
| Opal SM, Cross A, Palmer M, Almazan R. "Group B streptococcal sepsis in adults and infants. Contrasts and comparisons." Arch Intern Med, vol. 148, no. 3, 1988, pp. 641-5. |
| DeBuono BA, Brondum J, Kramer JM, Gilbert RJ, Opal SM. "Plasmid, serotypic, and enterotoxin analysis of Bacillus cereus in an outbreak setting." Journal of clinical microbiology, vol. 26, no. 8, 1988, pp. 1571-4. |
| Singh V, Opal SM. "Rocky Mountain spotted fever in Rhode Island: case report and review of its occurrence during the past ten years." Rhode Island medical journal (2013), vol. 71, no. 4, 1988, pp. 155-8. |
| Opal SM, Johnson-Winegar AD, Cross AS. "Staphylococcal scalded skin syndrome in two immunocompetent adults caused by exfoliatin B-producing Staphylococcus aureus." Journal of clinical microbiology, vol. 26, no. 7, 1988, pp. 1283-6. |
| Opal SM, Cross A, Gemski P, Lyhte LW. "Survey of purported virulence factors of Escherichia coli isolated from blood, urine and stool." European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, vol. 7, no. 3, 1988, pp. 425-7. |
| Mayer KH, Opal SM. "Antibacterial therapy in patients with malignancies." Cancer metastasis reviews, vol. 5, no. 3, 1987, pp. 271-93. |
| Goodwin RA, Opal SM. "Polymicrobial bacteremic pneumonia: report of three cases caused by Staphylococcus aureus and Streptococcus pneumoniae." The American review of respiratory disease, vol. 136, no. 4, 1987, pp. 1005-6. |
| Mayer KH, Opal SM. "Therapeutic approaches for AIDS and HIV infection." Rhode Island medical journal (2013), vol. 70, no. 1, 1987, pp. 27-33. |
| Opal SM, Reller LB, Harrington G, Cannady P Jr. "Aspergillus clavatus endocarditis involving a normal aortic valve following coronary artery surgery." Reviews of infectious diseases, vol. 8, no. 5, 1986, pp. 781-5. |
| Opal SM, Asp AA, Cannady PB Jr, Morse PL, Burton LJ, Hammer PG 2nd. "Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction." The Journal of Infectious Diseases, vol. 153, no. 3, 1986, pp. 634-7. |
| Witte MC, Opal SM, Gilbert JG, Pluss JL, Thomas DA, Olsen JD, Perry ME. "Incidence of fever and bacteremia following transbronchial needle aspiration." Chest, vol. 89, no. 1, 1986, pp. 85-7. |
| Opal SM, Saxon JR. "Intracranial infection by Vibrio alginolyticus following injury in salt water." Journal of clinical microbiology, vol. 23, no. 2, 1986, pp. 373-4. |
| Pluss JL, Opal SM. "Pulmonary sporotrichosis: review of treatment and outcome." Medicine, vol. 65, no. 3, 1986, pp. 143-53. |
| Pluss JL, Opal SM. "An additional case of pulmonary Pseudallescheria boydii improved with ketoconazole therapy." Chest, vol. 87, no. 6, 1985, pp. 843. |
| Willis SM, Opal SM, Fitzpatrick JE. "Cytophagic histiocytic panniculitis. Systemic histiocytosis presenting as chronic, nonhealing, ulcerative skin lesions." Arch Dermatol, vol. 121, no. 7, 1985, pp. 910-3. |
| Wilkerson RD, Taylor DC, Opal SM, Curl WW. "Nocardia asteroides sepsis of the knee." Clinical Orthopaedics and Related Research®, no. 197, 1985, pp. 206-8. |
| Harpster WH, Gonzalez C, Opal SM. "Pansinusitis caused by the fungus Drechslera." Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, vol. 93, no. 5, 1985, pp. 683-5. |
| Morse PL, Opal SM. "Adsorption of Clostridium difficile antiserum for rapid detection of toxin." Diagnostic microbiology and infectious disease, vol. 2, no. 2, 1984, pp. 169. |
| Piziak MV, Woodbury C, Berliner D, Takafuji E, Kirkpatrick J, Opal S, Tramont E. "Resistance trends of Neisseria gonorrhoeae in the Republic of Korea." Antimicrobial Agents and Chemotherapy, vol. 25, no. 1, 1984, pp. 7-9. |
| Cross AS, Opal S, Kopecko DJ. "Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance." Arch Intern Med, vol. 143, no. 11, 1983, pp. 2075-80. |
| Opal S, Cross A, Gemski P. "K antigen and serum sensitivity of rough Escherichia coli." Infection and Immunity, vol. 37, no. 3, 1982, pp. 956-60. |
| Opal SM, Pittman DL, Hofeldt FE. "Testicular sarcoidosis." The American Journal of Medicine, vol. 67, no. 1, 1979, pp. 147-50. |
1. Tressel SL, Kaneider NC, Foley C, Simon DJ, Koukos G, Agarwal A, Covic L, Opal SM, Kuliopulos A. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011; 3:1-15.
2. Artenstein A, Opal SM. The pro-protein convertases: The importance of being PC.New Engl J Med 2011; 365(26): 2507-2718
3. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Resp Crit Care Med 2011;32(5): 599-580.
4. Christaki E, Anyfanti P, Opal SM. Immunomodulation in sepsis revisited. Expert Rev anti-Infective Therapy. 2011; 9(11): 1-20.
6. Artenstein A, Opal SM. Current existing and potential novel treatment strategies for systemic anthrax infection. Clin Infect Dis 2012; 54(8):1148-1161.
7. Kellum J, Lemaeire N, Opal SM. The prevention of acute kidney injury secondary to antibiotics. Kidney International 2012; 2(1suppl) 61-65.
8. LaRosa S, Opal SM. Immune aspects of sepsis and hope for new therapeutics. Current Infect Dis Reports. 2012; 14(5): 474-483.
9. Christaki E, Lazaridis N, Opal SM. Receptor for advanced glycation end products in bacterial infections: Is there a role for immune modulation of RAGE in the treatment of infection? Current Opin Infect Dis 2012; 25(3):304-311.
10. Vincent J-L, Opal SM, Marshall J, Tracey K. Definitions for sepsis: Time for a change. Lancet 2013; 381:774-775.
11. Hurley JC, Opal SM. Prognostic value of endotoxemia in patients with gram-negative bacteremia is species dependent: an individual patient data meta-analysis. J Innate Immun 2013 (in press).
12. Ramachandran G, Tulapurkar ME, Harris KM, Arad G, Shivran A, Shemesh R, De Tolla LJ, Benazzi C, Opal SM, , Kaempfer R, Cross AS. A peptide antagonist of CD 28 signaling attenuates toxic shock and necrotizing soft tissue infection induced by Streptococcus pyogenes. J Infect Dis 2013; 206(12):1869-77.
13. Dellinger P, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Servansky J, Sprung CL, Douglas IS, Jaeschke R, Osborn T, Nunnally M, Townshead SR, Reinhart K, Kleinpell R, Angus D, Deutschman CS, Machado F, Rubenfeld, G, Webb S, Beale R J, Vincent J-L, Moreno R, for the surviving sepsis campaign guidelines committee. The surviving sepsis guidelines: 2012. Crit Care Med 2013;41(2):580-637.
14. Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldower LL, Demetriades D, Talvig P, Schreiber M, Ham B, Cohen M, Opal SM, et al. A Novel Drug for Treatment of Necrotizing Soft Tissue Infections: Results of a Phase 2a Randomized Controlled Trial of AB103, a CD28 Co-stimulatory Receptor Modulator. JAMA Surgery (in press).
15. Sim T, Browne SK, Holland S, Vigliani M, Zachary D, Rosen L, Opal SM. Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12 auto antibodies. J Clin Immunol 2013;33(6):1057-61.
16. Pop-Vicas A, Opal SM. The clinical impact of multidrug resistant gram-negative bacilli in the management of septic shock. Virulence 2014;5(1):1-7.
17. LaRosa S, Opal SM. Sepsis and septic shock.. American College of Physicians Medicine. Infectious Disease. ACP Medicine (Online). 2013; 10: (in press)
18. Angione S, Inde Z, Beck C, Artenstein A, Opal SM, Tripathi A. Microdroplet sandwich real-time RT-PCR for detection of pandemic and seasonal influenza subtypes. PLoS ONE 2013;8(9)13: e73497
19. Opal SM, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugenier T, Parrotin D, Tidswell M, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized study. JAMA 2013;309(11): 1154-1162.
here to add scholarly works.| Trainee | Armed Forces Institute of Pathology, Walter Reed Army Institute of Research, tropical medicine | 1981-1981 | Washington, D.C. |
| Fellow | Walter Reed Army Medical Center, infectious diseases | 1980-1982 | Washington, D.C. |
| Chief Resident | Fitzsimons Army Medical Center, medicine | 1978-1979 | Denver, CO |
| Resident | Fitzsimons Army Medical Center, internal medicine | 1977-1979 | Denver, CO |
| Intern | Fitzsimons Army Medical Center, internal medicine | 1976-1977 | Denver, CO |
| License for Use of Radioactive Isotopes in Biomedical Research | 1987-Present | #7B-043-01 | |
| DEA | 1985-Present | #B00997518 | |
| Medical License | Rhode Island | 1985-Present | #6676 |
| Certification | American Board of Internal Medicine, Infectious disease | 1984- | |
| Certification | American Board of Internal Medicine, Internal medicine | 1979- | |
| Brown University | - | #10027870 |
| Active Staff Physician. Roger Williams Medical Center, 1995-2000 |
| Consulting Staff; Attending Physician. Rhode Island Hospital, 1989-Present |
| Consulting Staff; Attending Physician. The Miriam Hospital, 1986-Present |
| Active Medical Staff; Attending Physician. Memorial Hospital of Rhode Island, 1985-Present |
| Director. Memorial Hospital of Rhode Island, 1985-Present |
| Chief. Fitzsimons Army Medical Center, 1983-1985 |
| Assistant Chief. Fitzsimons Army Medical Center, 1982-1983 |
